Notable Labs Income from Continuous Operations 2013-2024 | NTBLQ

Notable Labs income from continuous operations from 2013 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Notable Labs Annual Income from Continuous Operations
(Millions of US $)
2023 $-11
2022 $-14
2021 $-30
2020 $-24
2019 $-19
2018 $-20
2017 $-10
2016 $-16
2015 $-15
2014 $-17
2013 $-17
2012 $-12
Notable Labs Quarterly Income from Continuous Operations
(Millions of US $)
2024-06-30 $-5
2024-03-31 $-4
2023-12-31 $-0
2023-09-30 $-1
2023-06-30 $-3
2023-03-31 $-6
2022-12-31 $15
2022-09-30 $-9
2022-06-30 $-9
2022-03-31 $-10
2021-12-31 $-9
2021-09-30 $-7
2021-06-30 $-8
2021-03-31 $-6
2020-12-31 $-7
2020-09-30 $-6
2020-06-30 $-6
2020-03-31 $-5
2019-12-31 $-6
2019-09-30 $-5
2019-06-30 $-5
2019-03-31 $-4
2018-12-31 $-4
2018-09-30 $-5
2018-06-30 $-4
2018-03-31 $-7
2017-12-31 $6
2017-09-30 $-7
2017-06-30 $-5
2017-03-31 $-5
2016-12-31 $-5
2016-09-30 $-3
2016-06-30 $-3
2016-03-31 $-5
2015-12-31 $-3
2015-09-30 $-6
2015-06-30 $-3
2015-03-31 $-3
2014-12-31 $-5
2014-09-30 $-4
2014-06-30 $-4
2014-03-31 $-5
2013-12-31
2013-09-30 $-5
2012-12-31
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.000B $0.000B
Notable Labs Ltd. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Notable Labs Ltd., formerly known as Vascular Biogenics Ltd., is based in FOSTER CITY, Calif.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00
Ocuphire Pharma (IRD) $0.000B 0.00